Cited by 826Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Open access

Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H., Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E., Lindholm, Lars H., Nieminen, Markku S., Devereux, Richard B.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.10.068

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.10.068

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citation
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 101–200 of 819

Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial)
Aksnes, T. A., Schmieder, R. E., Kjeldsen, S. E., Ghani, S., Hua, T. A., & Julius, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.10.025 · Cited by 144
Self-citation
Patients With Atrial Fibrillation in a Primary Care Setting: Val-FAAP Study
Barrios, V., Calderón, A., Escobar, C., & de la Figuera, M. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.09.004 · Cited by 144
The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism
Rossi, G. P., Bisogni, V., Bacca, A., Belfiore, A., Cesari, M., Concistrè, A., Pinto, R. D., Fabris, B., Fallo, F., Fava, C., et al. (2020) · International Journal of Cardiology Hypertension · doi:10.1016/j.ijchy.2020.100029 · Cited by 140
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008)
JCS Joint Working Group (2010) · Circulation Journal · doi:10.1253/circj.cj-88-0001 · Cited by 137
Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies
Menezes, A. R., Lavie, C. J., DiNicolantonio, J. J., O’Keefe, J. H., Morin, D. P., Khatib, S., & Milani, R. V. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.022 · Cited by 141
Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis
Lavie, C. J., Patel, D. A., Milani, R. V., Ventura, H. O., Shah, S. B., & Gilliland, Y. E. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.05.003 · Cited by 135
Atrial fibrillation and stroke
Choi, S. E., Sagris, D., Hill, A. M., Lip, G. Y. H., & Abdul‐Rahim, A. H. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2160319 · Cited by 142
Electrocardiographic predictors of atrial fibrillation
Perez, M. V., Dewey, F. E., Marcus, R. R., Ashley, E. A., Al‐Ahmad, A., Wang, P. J., & Froelicher, V. F. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.08.002 · Cited by 134
Structural remodeling in atrial fibrillation
Corradi, D., Callegari, S., Maestri, R., Benussi, S., & Alfieri, O. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1370 · Cited by 136
Prevention of Recurrent Lone Atrial Fibrillation by the Angiotensin-II Converting Enzyme Inhibitor Ramipril in Normotensive Patients
Belluzzi, F., Sernesi, L., Preti, P. S., Salinaro, F., Fonte, M. L., & Perlini, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.071 · Cited by 132
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132
Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction
Hanna, I. R., Heeke, B., Bush, H., Brosius, L., King-Hageman, D., Dudley, S. C., Beshai, J. F., & Langberg, J. J. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.05.010 · Cited by 132
Left atrial global and regional function in patients with paroxysmal atrial fibrillation has already been impaired before enlargement of left atrium: velocity vector imaging echocardiography study
Kojima, T., Kawasaki, M., Tanaka, R., Ono, K., Hirose, T., Iwama, M., Watanabe, T., Noda, T., Watanabe, S., Takemura, G., et al. (2011) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ejechocard/jer281 · Cited by 131
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version
Ogawa, S., Aizawa, Y., Atarashi, H., Inoue, H., Kamakura, S., Koretsune, Y., Kumagai, K., Mitamura, H., Okumura, K., Sugi, K., et al. (2010) · Japanese Circulation Journal-english Edition · Cited by 130
Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS
Cea‐Calvo, L., Redón, J., Lozano, J. V., Fernández, C., Martí-Canales, J. C., Llisterri, J. L., González‐Esteban, J., & Aznar, J. (2007) · Revista Española de Cardiología · doi:10.1157/13107118 · Cited by 128
European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)
Görenek, B., Pelliccia, A., Benjamin, E. J., Boriani, G., Crijns, H. J. G. M., Fogel, R. I., Gelder, I. C. V., Halle, M., Kudaiberdieva, G., Lane, D. A., et al. (2016) · EP Europace · doi:10.1093/europace/euw242 · Cited by 134
Blockade of the renin–angiotensin–aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials
Khatib, R., Joseph, P., Briel, M., Yusuf, S., & Healey, J. S. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.02.009 · Cited by 126
Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients
Horio, T., Iwashima, Y., Kamide, K., Tokudome, T., Yoshihara, F., Nakamura, S., & Kawano, Y. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833a7dfe · Cited by 119
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Raimondo, D. D., Tuttolomondo, A., Buttà, C., Miceli, S., Licata, G., & Pinto, A. V. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481282 · Cited by 120
Molecular Genetics of Atrial Fibrillation
Tsai, C., Lai, L., Hwang, J., Lin, J.-L., & Chiang, F. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.072 · Cited by 119
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Goette, A., Bukowska, A., Lendeckel, U., Erxleben, M., Hammwöhner, M., Strugala, D., Pfeiffenberger, J., Röhl, F., Huth, C., Ebert, M. P. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.730101 · Cited by 117
Is Atrial Fibrillation a Preventable Disease?
Du, X., Dong, J., & Ma, C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.020 · Cited by 117
Atrial fibrillation and arterial hypertension
Kallistratos, M. S., Poulimenos, L. E., & Manolis, A. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.007 · Cited by 114
Hypertension and cerebrovascular damage
Veglio, F., Paglieri, C., Rabbia, F., BISBOCCI, D., Bergui, M., & Cerrato, P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.10.028 · Cited by 116
Candesartan in the prevention of relapsing atrial fibrillation
Tveit, A., Grundvold, I., Olufsen, M., Seljeflot, I., Abdelnoor, M., Arnesen, H., & Smith, P. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.08.086 · Cited by 112
Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis
Jibrini, M. B., Molnar, J., & Arora, R. R. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31804beb59 · Cited by 111
Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management
Ma, J., Chen, Q., & Ma, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16350 · Cited by 111
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Kirchhof, P. F., Bax, J. J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosío, F. G., Crijns, H. J. G. M., Diener, H., Goette, A., et al. (2009) · EP Europace · doi:10.1093/europace/eup124 · Cited by 112
Atrial Fibrillation Therapy Now and in the Future
Woods, C. E., & Olgin, J. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302362 · Cited by 109
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure
Shimano, M., Tsuji, Y., Inden, Y., Kitamura, K., Uchikawa, T., Harata, S., Nattel, S., & Murohara, T. (2007) · Heart Rhythm · doi:10.1016/j.hrthm.2007.12.010 · Cited by 110
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy
Khan, N. A., Hemmelgarn, B. R., Padwal, R. S., Larochelle, P. M., Mahon, J. L., Lewanczuk, R. Z., McAlister, F. A., Rabkin, S. W., Hill, M. D., Feldman, R. D., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70798-5 · Cited by 109
Prognostic Implications of Left Ventricular Hypertrophy
Stewart, M. H., Lavie, C. J., Shah, S. B., Englert, J. A. R., Gilliland, Y. E., Qamruddin, S., Dinshaw, H. K., Cash, M. E., Ventura, H. O., & Milani, R. V. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.11.002 · Cited by 111
Recent hypertension trials
Williams, B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.069 · Cited by 108
Antihypertensive treatment and risk of atrial fibrillation: a nationwide study
Marott, S. C. W., Nielsen, S. F., Benn, M., & Nordestgaard, B. G. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht507 · Cited by 107
Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies
Carr, A. A., Kowey, P. R., Devereux, R. B., Brenner, B. M., Dahlöf, B., Ibsen, H., Lindholm, L. H., Lyle, P. A., Snapinn, S. M., Zhang, Z., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.061 · Cited by 107
Self-citation
Atrial Fibrillation: Basic Mechanisms, Remodeling and Triggers
Shiroshita-Takeshita, A., Brundel, B. J. J. M., & Nattel, S. (2005) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-005-2362-y · Cited by 107
Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs
Schaer, B. A., Schneider, C., Jick, S. S., Conen, D., Osswald, S., & Meier, C. R. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00005 · Cited by 107
Electrical and Structural Remodeling: Role in the Genesis and Maintenance of Atrial Fibrillation
SCHOONDERWOERD, B. A., Gelder, I. C. V., van Veldhuisen, D. J., van den Berg, M. P., & Crijns, H. J. G. M. (2005) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2005.06.014 · Cited by 106
European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)
Görenek, B., Pelliccia, A., Benjamin, E. J., Boriani, G., Crijns, H. J. G. M., Fogel, R. I., Gelder, I. C. V., Halle, M., Kudaiberdieva, G., Lane, D. A., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316676037 · Cited by 104
Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes
Boriani, G., Vitolo, M., Diemberger, I., Proietti, M., Valenti, A. C., Malavasi, V. L., & Lip, G. Y. H. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab147 · Cited by 105
Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])
Parkash, R., Wells, G. A., Sapp, J. L., Healey, J. S., Tardif, J.-C., Greiss, I., Rivard, L., Roux, J.-F., Gula, L., Nault, I., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026230 · Cited by 101
Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications
Lau, Y.-F., Yiu, K., Siu, C.-W., & Tse, H.-F. (2011) · Journal of Human Hypertension · doi:10.1038/jhh.2011.105 · Cited by 103
Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation
Lin, C., & Pan, C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7408-8 · Cited by 100
Endothelial dysfunction and pathophysiological correlates in atrial fibrillation
Guazzi, M., & Arena, R. A. (2008) · Heart · doi:10.1136/hrt.2007.135277 · Cited by 100
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Klein, P., Friedman, A., Hameed, M. Q., Kaminski, R. M., Bar‐Klein, G., Klitgaard, H., Koepp, M. J., Jóźwiak, S., Prince, D. A., Rotenberg, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16450 · Cited by 100
Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction – A LIFE review
Bang, C. N., Devereux, R. B., & Okin, P. M. (2014) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2014.07.003 · Cited by 99
Self-citation
Losartan and Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients
Fogari, R., Mugellini, A., Destro, M., Corradi, L., Zoppi, A., Fogari, E., & Rinaldi, A. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000193808.99773.28 · Cited by 99
Management of atrial fibrillation: Figure 1
Lip, G. Y. H., & Tello-Montoliu, A. (2006) · Heart · doi:10.1136/hrt.2005.071555 · Cited by 99
Association of Left Atrial Function Index with Atrial Fibrillation and Cardiovascular Disease: The Framingham Offspring Study
Sardana, M., Lessard, D., Tsao, C. W., Parikh, N. I., BARTON, B. A., Nah, G., Thomas, R. C., Cheng, S. C., Schiller, N. B., Aragam, J. R., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008435 · Cited by 97
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 97
Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management
Gumprecht, J. J., Domek, M., Lip, G. Y. H., & Shantsila, A. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0279-7 · Cited by 98
The Year in Hypertension
Williams, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.074 · Cited by 96
Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9–10, 2013
Wagoner, D. R. V., Piccini, J. P., Albert, C. M., Anderson, M. E., Benjamin, E. J., Brundel, B. J. J. M., Califf, R. M., Calkins, H. G., Chen, P., Chiamvimonvat, N., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.11.011 · Cited by 95
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment
Inciardi, R. M., Bonelli, A., Biering‐Sørensen, T., Cameli, M., Pagnesi, M., Lombardi, C., Solomon, S. D., & Metra, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2562 · Cited by 95
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
Bode, D., Pronto, J. R. D., Schiattarella, G. G., & Voigt, N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01038-6 · Cited by 98
Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study
Salehian, O., Healey, J. S., Stambler, B. S., Alnemer, K., Almerri, K., Grover, J., Bata, I. R., Mann, J. F. E., Matthew, J., Pogue, J. M., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.04.062 · Cited by 92
Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes
Dzeshka, M. S., Shahid, F., Shantsila, A., & Lip, G. Y. H. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx013 · Cited by 91
Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation
Richter, B., Derntl, M., Marx, M., Lercher, P., & Gössinger, H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.09.006 · Cited by 91
Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge
Nso, N., Bookani, K. R., Metzl, M. D., & Radparvar, F. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12473 · Cited by 87
Relations of Arterial Stiffness and Brachial Flow–Mediated Dilation With New-Onset Atrial Fibrillation
Shaikh, A. Y., Wang, N., Yin, X., Larson, M. G., Vasan, R. S., Hamburg, N. M., Magnani, J. W., Ellinor, P. T., Lubitz, S. A., Mitchell, G. F., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07650 · Cited by 86
Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients
Okin, P. M., Hille, D. A., Larstorp, A. C. K., Wachtell, K., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05728 · Cited by 82
Self-citation
Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation
Carnagarin, R., Kiuchi, M. G., Ho, J. K., Matthews, V. B., & Schlaich, M. P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01058 · Cited by 81
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?
Reudelhuber, T. L., Bernstein, K. E., & Delafontaine, P. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.075085 · Cited by 80
Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up
Naruse, Y., Tada, H., Sekiguchi, Y., Machino, T., Ozawa, M., Yamasaki, H., Igarashi, M., Kuroki, K., Ito, Y., Murakoshi, N., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.10.047 · Cited by 79
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 79
The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE‐Is and ARBS
Novo, G., Guttilla, D., Fazio, G., Cooper, D., & Novo, S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03234.x · Cited by 80
The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 91
Association of Electrocardiographic and Imaging Surrogates of Left Ventricular Hypertrophy With Incident Atrial Fibrillation
Chrispin, J., Jain, A., Soliman, E. Z., Güallar, E., Alonso, Á., Heckbert, S. R., Bluemke, D. A., Lima, J. A. C., & Nazarian, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.066 · Cited by 77
Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels
Ogunsua, A., Shaikh, A. Y., Ahmed, M., & McManus, D. D. (2015) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-11-4-228 · Cited by 80
Effect of Valsartan and Ramipril on Atrial Fibrillation Recurrence and P-wave dispersion in Hypertensive Patients With Recurrent Symptomatic Lone Atrial Fibrillation
Fogari, R., Derosa, G., Ferrari, I., Corradi, L., Zoppi, A., Lazzari, P., Santoro, T., Preti, P. S., & Mugellini, A. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.217 · Cited by 76
Prevention of Stroke in Patients with Hypertension
Dahlöf, B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.010 · Cited by 78
Self-citation
Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy
Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Dahlöf, B., & Devereux, R. B. (2013) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.112.977777 · Cited by 75
Self-citation
Arterial stiffness is associated with left atrial size in hypertensive patients
Lantelme, P., Laurent, S., Besnard, C., Bricca, G., Vincent, M., Legedz, L., & Milon, H. (2008) · Archives of cardiovascular diseases · doi:10.1016/s1875-2136(08)70253-5 · Cited by 73
Novel Approaches for Pharmacological Management of Atrial Fibrillation
Ehrlich, J. R., & Nattel, S. (2009) · Drugs · doi:10.2165/00003495-200969070-00001 · Cited by 73
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Adam, O., Neuberger, H., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.760892 · Cited by 73
Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes
Saygili, E., Rana, O. R., Saygılı, E., Reuter, H., Frank, K. F., Schwinger, R. H. G., Müller‐Ehmsen, J., & Zobel, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00546.2006 · Cited by 73
The frail renin–angiotensin system
Abadir, P. M. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.08.004 · Cited by 70
Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions
Gerth, A., Limbourg, T., Lewalter, T., Goette, A., Wegscheider, K., Treszl, A., Meinertz, T., Oeff, M., Ravens, U., BREITHARDT, G. E., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-02-0070 · Cited by 70
Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery
Cardinale, D. M., Sandri, M. T., Colombo, A., Salvatici, M., Tedeschi, I., Bacchiani, G., Beggiato, M., Meroni, C. A., Civelli, M., Lamantia, G., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001626 · Cited by 70
Angiotensin II Type 1 Receptor Blocker Prevents Atrial Structural Remodeling in Rats with Hypertension Induced by Chronic Nitric Oxide Inhibition
Okazaki, H., Minamino, T., Tsukamoto, O., Kim, J., OKADA, K.-I., Myoishi, M., Wakeno, M., Takashima, S., Mochizuki, N., & Kitakaze, M. (2006) · Hypertension Research · doi:10.1291/hypres.29.277 · Cited by 70
Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
Burnier, M. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700602 · Cited by 69
Impact of the Duration and Degree of Hypertension and Body Weight on New-Onset Atrial Fibrillation
Kim, Y. G., Han, K., Choi, J., Boo, K. Y., Kim, D. Y., Oh, S., Lee, K., Shim, J., Kim, J. S., & Kim, Y. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13672 · Cited by 69
The angiotensin–calcineurin–NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes
Saygili, E., Rana, O. R., Meyer, C., Gemein, C., Andrzejewski, M. G., Ludwig, A., Weber, C., Schotten, U., Krüttgen, A., Weis, J., et al. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-008-0772-6 · Cited by 68
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
Wachtell, K., Gerdts, E., Aurigemma, G. P., Boman, K., Dahlöf, B., Nieminen, M. S., Olsen, M. H., Okin, P. M., Palmieri, V., Rokkedal, J. E., et al. (2010) · Blood Pressure · doi:10.3109/08037051.2010.481811 · Cited by 67
Self-citation
An update on atrial fibrillation in 2014: From pathophysiology to treatment
Ferrari, R., Bertini, M., Blomström‐Lundqvist, C., Dobrev, D., Kirchhof, P. F., Pappone, C., Ravens, U., Tamargo, J. L., Tavazzi, L., & Vicedomini, G. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.089 · Cited by 67
Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism
Seccia, T. M., Caroccia, B., Adler, G. K., Maiolino, G., Cesari, M., & Rossi, G. P. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08956 · Cited by 68
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies
Verdecchia, P., Dagenais, G. R., Healey, J. S., Gao, P., Dans, A. L., Chazova, I. E., Binbrek, A. S., Iacobellis, G., Ferreira, R., Holwerda, N. J., et al. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283522a51 · Cited by 67
Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor 1
Tsai, C., Tseng, C.-D., Hwang, J., Wu, C., Yu, C., Wang, Y., Chen, W., Lai, L., Chiang, F., & Lin, J.-L. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq322 · Cited by 66
Raised Plasma Aldosterone and Natriuretic Peptides in Atrial Fibrillation
Dixen, U., Ravn, L. S., Soeby-Rasmussen, C., Paulsen, A. W., Parner, J., Frandsen, E. L., & Jensen, G. B. (2006) · Cardiology · doi:10.1159/000095671 · Cited by 65
Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study
Almroth, H., Höglund, N., Boman, K., Englund, A., Jensen, S. M., Kjellman, B., Tornvall, P., & Rosenqvist, M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp006 · Cited by 65
Telmisartan: just an antihypertensive agent? A literature review
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632367 · Cited by 65
Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications
Clémenty, N., Piver, É., Bisson, A., André, C., Bernard, A., Pierre, B., Fauchier, L., & Babuty, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040976 · Cited by 65
The Pleiotropic Effects of Angiotensin Receptor Blockers
Chrysant, S. G., & Chrysant, G. S. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05264.x · Cited by 65
Peri-Atrial Epicardial Adipose Tissue Is Associated With New-Onset Nonvalvular Atrial Fibrillation
Nakanishi, K., Fukuda, S., Tanaka, A., Otsuka, K., Sakamoto, M., Taguchi, H., Yoshikawa, J., Shimada, K., & Yoshiyama, M. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0637 · Cited by 63
Diastolic dysfunction and atrial fibrillation
Nagarakanti, R., & Ezekowitz, M. D. (2008) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-008-9203-8 · Cited by 63
Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha)
Bjarnason‐Wehrens, B., Held, K., Hoberg, E., Karoff, M., & Rauch, B. (2007) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-007-0001-0 · Cited by 64
Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it
Nattel, S., Sager, P. T., Hüser, J., Heijman, J., & Dobrev, D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab093 · Cited by 64
Atrial Fibrillation Detection and Management in Hypertension
Gawalko, M. M., & Linz, D. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19459 · Cited by 64
Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy
Larstorp, A. C. K., Ariansen, I., Gjesdal, K., Olsen, M. H., Ibsen, H., Devereux, R. B., Okin, P. M., Dahlöf, B., Kjeldsen, S. E., & Wachtell, K. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195032 · Cited by 65
Self-citation

Authors: Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
Affiliations: Cornell University (US)
Helsinki University Hospital (FI)
Haukeland University Hospital (NO)
Glostrup Hospital (DK)
Sahlgrenska University Hospital (SE)
University of Michigan (US)
Oslo University Hospital (NO)
University Hospital of Umeå (SE)
Corresponding author: Wachtell, Kristian
ORCID: Wachtell, Kristian
Lehto, Mika
Gerdts, Eva
Olsen, Michael H.
Hornestam, Björn
Kjeldsen, Sverre E.
Lindholm, Lars H.
Nieminen, Markku S.
Devereux, Richard B.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-03
Volume: 45
Issue: 5
Pages: 712-719
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.10.068
OpenAlex: W2147918774
Cited by: 826
References: 27
Citations by year: 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
FWCI: 64.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3096 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Rigshospitalet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
MeSH terms: Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks